Clinical Trial Update: Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating an HLA-A*2402 restricted peptide vaccine in patients with esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• HLA-A*2402 restricted peptide vaccine

Snippet

Sponsor: Tokyo University | Conditions: Esophageal Cancer | Phase 1, Phase 2 | Status: COMPLETED